社区

''For instance, in a September 2021 Nature paper2, a team co-led by Paul Bieniasz, a virologist at Rockefeller University in New York City, engineered a highly mutated version of spike — in a virus incapable of causing COVID-19 — that shares numerous mutations with Omicron. The ‘polymutant spike’ proved fully resistant to neutralizing antibodies from most of the people they tested, who had either received two doses of an mRNA vaccine or recovered from COVID-19. With Omicron, “we expect there to be a significant hit”, says Bieniasz.''
The thing is, and I get most here don't understand this, is all antibodies created by the vaccines are not the same (if they did the UK booster news would not have tanked the share price 40 dollars).
It's why you just can't look at their levels and figure out efficacy percentages and durability length.
While mRNA vaccines target a very specific part of the spike protein (which mutations can change rapidly) NVAX uses the entire spike protein to generate an immune response....the result being you generate a much more robust antibody.
So....it's very possible mRNA vaccines will not work on Omicron yet NVAX will.
Yea, it's still unknown. Maybe Omicron is that different even NVAX can't keep up with up.
But imagine if it did....and how the share price would respond to such news???????
I'm going to guess it's close to 25% at this point it plays out like this.

$Novavax(NVAX)$ $Moderna, Inc.(MRNA)$